GXO Logistics Inc vs Eli Lilly And Co — how do they compare? GXO Logistics Inc trades at $46.47 (market cap $5.32B), while Eli Lilly And Co trades at $1,174.03 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 195.5× GXO Logistics Inc's market cap, and Eli Lilly And Co pays a 0.59% dividend while GXO Logistics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GXO Logistics Inc for 28 Days and Eli Lilly And Co for 93 Days on average.
| GXO | LLY | |
|---|---|---|
Market Cap | $5.32B | $1.04T |
Volume | 1,255,816 | 3,064,878 |
Sector | Industrials | Health |
52-Week High | $65.59 | $1.28K |
52-Week Low | $44.17 | $799.57 |
Typical Hold Time | 28 Days | 93 Days |
Enterprise Value | $10.67B | $1.09T |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
GXO trades at $46.58, up 1.28% today, with a neutral technical signal and strong analyst support. The company reported three consecutive quarterly EPS beats and is expanding through strategic partnerships, including a new 10-year logistics deal with Columbia Sportswear in Europe. Revenue grew to $13.18B in 2025, with a net income margin of 0.96%, though valuation metrics like a P/E of 41.03 appear elevated relative to profitability.
The outlook is positive, driven by operational improvements and industry tailwinds, but risks include margin pressures and high debt. With an 89% buy rating from analysts and a consensus price target of $66.67, the stock offers significant upside potential if execution aligns with growth initiatives.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →